RECURRENT ENDOMETRIAL CANCER
Clinical trials for RECURRENT ENDOMETRIAL CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ENDOMETRIAL CANCER trials appear
Sign up with your email to follow new studies for RECURRENT ENDOMETRIAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Cancer drug trial halted early – what happened?
Disease control TerminatedThis study tested an experimental drug called ART0380 in 36 people with advanced or metastatic solid tumors, including endometrial cancer. The goal was to see if the drug could shrink tumors. The trial was terminated early, so results are limited. Participants had to have finishe…
Matched conditions: RECURRENT ENDOMETRIAL CANCER
Phase: PHASE2 • Sponsor: Artios Pharma Ltd • Aim: Disease control
Last updated May 26, 2026 12:03 UTC
-
Promising cancer combo study halted after recruiting only 4 patients
Disease control TerminatedThis study aimed to see if a combination of two drugs, lenvatinib and pembrolizumab, could shrink tumors in Black women whose endometrial cancer had returned. Only 4 participants were enrolled before the study was stopped early. The goal was to measure how many patients responded…
Matched conditions: RECURRENT ENDOMETRIAL CANCER
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated May 26, 2026 12:02 UTC